المؤلفون: V. Matveev B., B. Alekseev Ya., B. Kamolov Sh., A. Markova S., В. Матвеев Б., Б. Алексеев Я., Б. Камолов Ш., А. Маркова С.

المصدر: Cancer Urology; Том 17, № 2 (2021); 83-92 ; Онкоурология; Том 17, № 2 (2021); 83-92 ; 1996-1812 ; 1726-9776

مصطلحات موضوعية: prostate cancer, androgen deprivation therapy, hormone therapy, luteinizing hormone-releasing hormone agonists, routine clinical practice, non-interventional study, рак предстательной железы, андроген-депривационная терапия, гормональная терапия, агонист лютеинизирующего гормона рилизинг-гормона, рутинная клиническая практика, неинтервенционное исследование

وصف الملف: application/pdf

Relation: https://oncourology.abvpress.ru/oncur/article/view/1466/1276; Злокачественные новообразования в России в 2018 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена - филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2019. 250 с.; Состояние онкологической помощи населению России в 2018 году. Под ред. А.Д. Каприна, В.В. Старин-ского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена - филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2019. 236 с.; Mottet N., Cornford P., van den Bergh R.C.N. et al. EAU-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. European Association of Urology, 2021. P. 212.; Seidenfeld J., Samson D.J., Hasselblad V. et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med 2000;132(7):566-77. DOI:10.7326/0003-4819-132-7200004040-00009; Rick F.G., Schally A.V. Bench-to-bedside development of agonists and antagonists of luteinizing hormone-releasing hormone for treatment of advanced prostate cancer. Urol Oncol 2015;33(6):270-4. DOI:10.1016/j.urolonc.2014.11.006.; Schally A.V., Block N.L., Rick F.G. Discovery of LHRH and development of LHRH analogs for prostate cancer treatment. Prostate 2017;77(9):1036-54. DOI:10.1002/pros.23360.; Liu S.V., Liu S., Pinski J. Luteinizing hormone-releasing hormone receptor targeted agents for prostate cancer. Expert Opin Investig Drugs 2011;20(6):769-78. DOI:10.1517/13543784.2011.574611.; Perez-Marrero R., Tyler R.C. A subcutaneous delivery system for the extended release of leuprolide acetate for the treatment of prostate cancer. Expert Opin Pharmacother 2004;5(2):447-57. DOI:10.1517/14656566.5.2.447.; Chu F.M., Jayson M., Dineen M.K. et al. A clinical study of 22.5 mg. La-2550: a new subcutaneous depot delivery system for leuprolide acetate for the treatment of prostate cancer. J Urol 2002;168(3):1199-203. DOI:10.1097/01.ju.0000023895.95963.1b.; Oefelein M.G., Feng A., Scolieri M.J. et al. Reassessment of the definition of castratelevels of testosterone: implications for clinical decision making. Urology 2000;56(6):1021-4. DOI:10.1016/s0090-4295(00)00793-7.; Матвеев В.Б., Маркова А.С. Финальные результаты проспективной многоцентровой наблюдательной программы RU-EGD-NI-001 по оценке эффективности и переносимости 6-месячной депо-формы Элигарда 45 мг у больных распространенным раком предстательной железы в рутинной клинической практике российских онкоурологов. Онкоурология 2017;13(2):79-86. DOI:10.17650/1726-9776-2017-13-2-79-86.; Tunn U.W. A 6-month depot formulation of leuprolide acetate is safe and effective in daily clinical practice: a non-interventional prospective study in 1273 patients. BMC Urology 2011;11:15. DOI:10.1186/1471-2490-11-15.; Montorsi F., Tomlinson P. Which luteinising hormone-releasing hormone agonist injection schedule do men with prostate cancer prefer? Results of a European patient survey. Eur Urol 2015;67(1):177-9. DOI:10.1016/j.eururo.2014.08.055.; Рак предстательной железы. Клинические рекомендации. Ассоциация онкологов России, 2020.; Рак предстательной железы. Клинические рекомендации. Министерство здравоохранения Российской Федерации, 2021.; Klotz L., O'Callaghan C., Ding K. et al. Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT. J Clin Oncol 2015;33(10):1151-6. DOI:10.1200/JCO.2014.58.2973.; https://oncourology.abvpress.ru/oncur/article/view/1466

الاتاحة: https://oncourology.abvpress.ru/oncur/article/view/1466
https://doi.org/10.17650/1726-9776-2021-17-2-83-92

المؤلفون: A. Panakhov D., K. Figurin M., B. Kamolov Sh., I. Seregin V., I. Sokolova N., А. Панахов Д., К. Фигурин М., Б. Камолов Ш., И. Серегин В., И. Соколова Н.

المصدر: Cancer Urology; Том 2, № 3 (2006); 30-33 ; Онкоурология; Том 2, № 3 (2006); 30-33 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2006-2-3

وصف الملف: application/pdf

Relation: https://oncourology.abvpress.ru/oncur/article/view/1165/1050; Herr H.W., Jakse G., Sheinfeld J. The T1 bladder tumor. Semin Urol 1990; 8: 254.; Holmang S., Hedelin H., Anderstrom C. et al. The importance of the depth of invasion in stage T1 bladder carcinoma: A prospective cohort study. J Urol 1997; 157: 800.; Hurle R., Losa A., Ranieri A. et al. Intravesical bacillus Calmette-Guerin in stage T1, grade 3 bladder cancer therapy: a 7-year follow-up. Urology 1999; 54: 258–63.; Cheng L., Weaver A.L., Neumann R.M. et al. Substaging of T1 bladder carcinoma based on the depth of invasion as measured by micrometer: a new proposal. Cancer 1999; 86: 1035.; Shahin O., Thalmann G.N., Rentsch C. et al. A retrospective analysis of 153 patients treated with or without intravesical BCG for primary stage T1 grade G3 bladder cancer: recurrence, progression, survival. J Urol 2003; 169: 96–100.; Heney N.M., Ahmed S., Flanagan M.J. et al. National Bladder Cancer Collaborative Group A: Superficial bladder cancer: progression and recurrence. J Urol 1983; 130: 1083.; Jakse G., Loidl W., Seeber G., Hofstadter F. Stage T1, grade 3 transitional carcinoma of the bladder: an unfavourable tumour. J Urol 1984;137:39–43.; Kaubisch S., Lum B.L., Reese J. et al. Stage T1 bladder cancer: grade is the primary determinant for risk of muscle invasion. J Urol 1991; 146: 28–31.; Lutzeyer W., Rübben H., Dahm H. Prognostic parameters in superficial bladder cancer: an analysis of 315 cases. J Urol 1982; 127: 250–2.; Baniel J., Grauss D., Engelstein D. et al. Intravesical bacillus treatment for Stage T1 grade 3 transitional cell carcinoma of the bladder. Urology 1998; 52: 785–9.; Brake M., Loertzer H., Horsch R. et al. Reccurence and progression of stage T1, grade 3 transitional cell carcinoma of the bladder following intravesical immunotherapy with bacillus Calmette-Guerin. J Urol 2000; 163: 1697–701.; Gohji K., Nomi M., Okamoto M. et al. Conservative therapy for stage T1b, grade 3 transitional cell carcinoma of the bladder. Urology 1999; 53: 308.; Klän R., Steiner U., Sauter T. et al: Zystektomie beim schlecht differenzierten T1-Harnblasenkarzinom—oft zu früh? Akt Urol 1998; 29: 53.; Lebret T., Gaudez F., Herve J.M. et al. Low-dose BCG instillations in the treatment of Stage T1 Grade 3 bladder tumors: recurrence, progression and success. Eur Urol 1998; 34: 67–72.; Pansadoro V., Emiliozzi P., De Paula F. et al. Long-term follow-up of T1G3 Transitional cell carcinoma of the bladder treated with intravesical bacille Calmette-Guerin: 18-year experience. Urology 2002; 59: 227–31.; Oosterlinck W., Lobel B., Jakse G. et al. The EAU Working group on Oncological Urology. European Association of Urology Guidelines on bladder cancer. Eur Urol 2002; 41: 105–12.; Cookson M.S, Herr H.W., Zhang Z.F. et al. The treated natural history of high risk superficial bladder cancer: 15-year out-come. J Urol 1997; 158: 62–7.; https://oncourology.abvpress.ru/oncur/article/view/1165

الاتاحة: https://oncourology.abvpress.ru/oncur/article/view/1165
https://doi.org/10.17650/1726-9776-2006-2-3-30-33

المؤلفون: V. Matveev B., A. Kirichek A., V. Safronova M., N. Kokosadze V., O. Khalmurzaev A., B. Kamolov Sh., L. Liubchenko N., В. Матвеев Б., А. Киричек А., В. Сафронова М., Н. Кокосадзе В., О. Халмурзаев А., Б. Камолов Ш., Л. Любченко Н.

المصدر: Cancer Urology; Том 15, № 1 (2019); 57-65 ; Онкоурология; Том 15, № 1 (2019); 57-65 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2019-15-1

مصطلحات موضوعية: metastatic prostate cancer, biomarker, PD-L1, hormonal therapy, time to castration resistance, survival, poor prognosis, метастатический рак предстательной железы, биомаркер, гормональная терапия, время до кастрационной резистентности, выживаемость, неблагоприятный прогноз

وصف الملف: application/pdf

Relation: https://oncourology.abvpress.ru/oncur/article/view/915/828; Заридзе Д.Г., Каприн А.Д., Стилиди И.С. Динамика заболеваемости злокачественными новообразованиями и смертности от них в России. Вопросы онкологии 2018;64(5):578—91.; Bray F., Ferlay J., Soerjomataram I. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018:68(6):394—424. DOI:10.3322/caac.21492. PMID: 30207593.; Алексеев Б.Я., Нюшко К.М., Каприн А.Д. Аналоги лютеинизирующего гормона рилизинг-гормона в терапии больных раком предстательной железы. Медицинский совет 2018;19:96-100. DOI:10.21518/2079-701X-2018-19-96-100.; Vale C.L., Burdett S., Rydzewska L.H. et al. Addition of docetaxel or bisphospho- nates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. Lancet Oncol 2016;17(2):243—56. DOI:10.1016/S1470-2045(15)00489-1. PMID: 26868352.; Rydzewska L.H.M., Burdett S., Vale C.L. et al. Adding abiraterone to androgen de¬privation therapy in men with metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis. Eur J Cancer 2017;84:88-101. DOI:10.1016/j.ejca.2017.07.003. PMID: 29573942.; Киричек А.А., Камолов Б.Ш., Матвеев В.Б. Обзор материалов конгресса Европейского общества медицинской онкологии (ESMO) 2017 г. Онкоурология 2017;13(4):133—40. DOI:10.17650/1726-9776-2017-13-4-133-140.; Feyerabend S., Saad F., Li T. et al. Survival benefit, disease progression and quality-of- life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: a network meta-analysis. Eur J Cancer 2018;103:78-87. DOI:10.1016/j.ejca.2018.08.010. PMID: 30218976.; Zhuan-Sun Y., Huang F., Feng M. et al. Prognostic value of PD-L1 overexpression for pancreatic cancer: evidence from a me- 19. ta-analysis. Onco Targets Ther 2017;10:5005-12. DOI:10.2147/OTT.S146383. PMID: 29081663.; Zhang M., Wang D., Sun Q. et al. Prognostic significance of PD-L1 expression and 18F-FDG PET/CT in surgical pul- 20. monary squamous cell carcinoma. Oncotarget 2017;8(31):51630—40. DOI:10.18632/oncotarget.18257. PMID: 28881674.; Li J., Wang P., Xu Y. Prognostic value of programmed cell death ligand 1 expression in patients with head and neck cancer: a systematic review and meta-analysis. 21. PLoS One 2017;12(6):e0179536. DOI:10.1371/journal.pone.0179536. PMID: 28604812.; Zhang M., Dong Y., Liu H. et al. The clinicopathological and prognostic significance of PD-L1 expression in gastric cancer: a meta-analysis of 10 studies with 1,901 patients. Sci Rep 2016;6:37933. 22. DOI:10.1038/screp37933. PMID: 27892511.; Suer E., Hamidi N., Akpinar C. et al. The effect of time to castration resistance on overall survival and success of docetaxel treatment in castration resistant prostate 23. cancer patients. Urol J 2019. DOI:10.22037/uj.y0i0.4497. PMID: 30636274.; Cornford P., Bellmunt J., Bolla M. et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: Treatment of relapsing, 24. metastatic, and castration-resistant prostate cancer. Eur Urol 2017;71(4):630—42. DOI:10.1016/j.euuro.2016.08.002. PMID: 27591931.; Topalian S.L., Drake C.G., Pardoll D.M. Targeting the PD-1/B7-H1 (PD-L1) path¬way to activate anti-tumor immunity. Curr Opin Immunol 2012;24(2):207—12. 25. DOI:10.1016/j.coi.2011.12.009. PMID: 22236695.; Pardoll D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12(4):252—64. DOI:10.1038/nrc3239. PMID: 22437870.; Martin A.M., Nirschl T.R., Nirschl C.J. 26. et al. Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance. Prostate Cancer Prostatic Dis 2015;18(4):325—32. DOI:10.1038/pcan.2015.39. PMID: 26260996.; Wise H.M., Hermida M.A., Leslie N.R. 27. Prostate cancer, PI3K, PTEN and prognosis. Clin Sci (Lond) 2017;131(3):197—210. DOI:10.1042/CS20160026. PMID: 28057891.; Thoma C. Prostate cancer: PD-L1 expression is common and indicates poor prognosis. Nat Rev Urol 2016;13(1):5. DOI:10.1038/nrurol.2015.287. PMID: 26620611.; Gevensleben H., Dietrich D., Golletz C. et al. The immune checkpoint regulator PD-L1 is highly expressed in aggressive primary prostate cancer. Clin Cancer Res 2016;22(8):1969—77. DOI:10.1158/1078-0432.CCR-15-2042. PMID: 26573597.; Gevensleben H., Holmes E.E., Goltz D. et al. PD-L1 promoter methylation is a prognostic biomarker for biochemical recurrence-free survival in prostate cancer patients following radical prostatectomy. Oncotarget 2016;7(48):79943—55. DOI:10.18632/oncotarget.13161. PMID: 27835597.; Ness N., Andersen S., Khanehkenari M.R. et al. The prognostic role of immune checkpoint markers programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) in a large, multicenter prostate cancer cohort. Oncotarget 2017:8(16):26789—801. DOI:10.18632/oncotarget.15817. PMID: 28460462.; Petitprez F., Fossati N., Vano Y. et al. PD- L1 expression and CD8+ T-cell infiltrate are associated with clinical progression in patients with node-positive prostate cancer. Eur Urol Focus 2017. DOI:10.1016/j.euf.2017.05.013. PMID: 28753812.; Zhao S.G., Lehrer J., Chang S.L. et al. The immune landscape of prostate cancer and nomination of PD-L2 as a potential therapeutic target. J Natl Cancer Inst 2018;111(3):djy141. DOI:10.1093/jnci/djy141. PMID: 30321406.; Li Y.M., Huang Q., Zhou Y. et al. The clinicopathologic and prognostic significance of programmed cell death ligand 1 (PD-L1) expression in patients with prostate cancer: a systematic review and meta-analysis. Front Pharmacol 2019:9:1494. DOI:10.3389/fphar.2018.01494. PMID: 30733677.; Massari F., Ciccarese C., Calio A. et al. Magnitude of PD-1, PD-L1 and T lymphocyte expression on tissue from castration-resistant prostate adenocarcinoma: an exploratory analysis. Target Oncol 2016;11(3):345—51. DOI:10.1007/s11523-015-0396-3. PMID: 26566945.; Hansen A.R., Massard C., Ott P.A. et al. Pembrolizumab for advanced adenocarcinoma: findings of the KEYNOTE-028 study. Ann Oncol 2018;29(8):1807—13. DOI:10.1093/annonc/mdy232. PMID: 29992241.; von Hardenberg J., Hartmann S., Nitsch- ke K. et al. Programmed death ligand 1 (PD-L1) status and tumor-infiltrating lymphocytes in hot spots of primary and liver metastases in prostate cancer with neuroendocrine differentiation. Clin Genitourin Cancer 2018. DOI:10.1016/j.clgc.2018.12.007. PMID: 30709785.; Haffner M.C., Guner G., Taheri D. et al. Comprehensive evaluation of programmed death-ligand 1 expression in primary and metastatic prostate cancer. Am J Pathol 2.018;188(6):1478—85. DOI:10.1016/j.aj-path.2018.02.014. PMID: 29577933.; Gannon P.O., Poisson A.O., Delvoye N. et al. Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients. J Immunol Methods 2009;348(1-2):9-17. DOI:10.1016/j.jim.2009.06.004. PMID: 19552894.; Mercader M., Bodner B.K., Moser M.T. et al. T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci USA 2001;98(25):14565—70. DOI:10.1073/pnas.251140998. PMID: 11734652.; Drake C.G. Prostate cancer as a model for tumour immunotherapy. Nat Rev Immunol 2010;10(8):580-93. DOI:10.1038/nri2817. PMID: 20651745.; Calagua C., Russo J., Sun Y et al. Expression of PD-L1 in hormone-naive and treated prostate cancer patients receiving neoadjuvant abiraterone acetate plus prednisone and leuprolide. Clin Cancer Res 2017;23(22):6812—22. DOI:10.1158/1078-0432.CCR-17-0807. PMID: 28893901.; Montironi R., Santoni M., Sotte V. et al. Emerging immunotargets and immunotherapies in prostate cancer. Curr Drug Targets 2016;17(7):777—82. PMID: 26898309.; Isaacsson Velho P., Antonarakis E.S. PD/PD-L1 pathway inhibitors in advanced prostate cancer. Expert Rev Clin Pharmacol 2018;11(5):475-86. DOI:10.1080/17512433.2018.1464388. PMID: 29641940.; https://oncourology.abvpress.ru/oncur/article/view/915

الاتاحة: https://oncourology.abvpress.ru/oncur/article/view/915
https://doi.org/10.17650/1726-9776-2019-15-1-57-65

المؤلفون: N. Apanovich V., V. Loginov I., P. Apanovich V., D. Sergeev A., T. Kazubskaya P., B. Kamolov Sh., E. Braga A., V. Matveev B., A. Karpukhin V., Н. Апанович В., В. Логинов И., П. Апанович В., Д. Сергеев А., Т. Казубская П., Б. Камолов Ш., Э. Брага А., В. Матвеев Б., А. Карпухин В.

المصدر: Cancer Urology; Том 14, № 4 (2018); 16-21 ; Онкоурология; Том 14, № 4 (2018); 16-21 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2018-14-4

مصطلحات موضوعية: gene expression, gene methylation, diagnostics, renal cell carcinoma, clear cell carcinoma, экспрессия генов, метилирование генов, диагностика, почечно-клеточный рак, светлоклеточный рак

وصف الملف: application/pdf

Relation: https://oncourology.abvpress.ru/oncur/article/view/886/821; Muglia V.F., Prando A. Renal cell carcinoma: histological classification and correlation with imaging findings. Radiol Bras 2015;48(3):166—74. DOI:10.1590/0100-3984.2013.1927. PMID: 26185343.; Ljungberg B., Bensalah K., Bex A. et al. Guidelines on Renal Cell Carcinoma. European association of urology 2014:70. DOI:10.1016/j.eururo.2015.01.005.; Caoili E.M., Davenport M.S. Role of per-cutaneous needle biopsy for renal masses. Semin Intervent Radiol 2014;31(1):20—6. DOI:10.1055/s-0033-1363839. PMID: 24596436.; Vetterlein M.W., Jindal T., Becker A. et al. Small renal masses in the elderly: contemporary treatment approaches and comparative oncological outcomes of nonsurgical and surgical strategies. Investig Clin Urol 2016;57(40):231—9. DOI:10.4111/icu.2016.57.4.231. PMID: 27437532.; Marconi L., Dabestani S., Lam T.B. et al. Systematic review and meta-analysis of diagnostic accuracy of percutaneous renal tumour biopsy. Eur Urol 2016;69:660-73. DOI:10.1016/j.eururo.2015.07.072.; Vrba L., Munoz-Rodriguez J.L., Stampfer M.R., Futscher B.W. miRNA gene promoters are frequent targets of aberrant DNA methylation in human breast cancer. PLoS One 2013;8(1):e54398. DOI:10.1371/journal.pone.0054398. PMID: 23342147.; Piletic K., Kunej T. MicroRNA epigenetic signatures in human disease. Arch Toxicol 2016;90(10):2405—19. DOI:10.1007/s00204-016-1815-7. PMID: 27557899.; Baylin S.B., Jones P.A. Epigenetic Determinants of Cancer. Cold Spring Harb Perspect Biol 2016;8(9):a019505. DOI:10.1101/cshperspect.a019505. PMID: 27194046.; Логинов В.И., Береснева Е.В., Казубская Т.П. и др. Метилирование 10 генов микроРНК при светлоклеточном раке почки и их диагностическое значение. Онкоурология 2017;3(13):27—33. DOI:10.17650/1726-9776-2017-13-3-27-33.; Аланович Н.В., Петерс М.В., Коротаева А.А. и др. Молекулярно-генетическая диагностика светлоклеточного почечно-клеточного рака. Онкоурология 2016;12(4):14—8. DOI:10.17650/1726-9776-2016-12-4-16-20.; Loginov V.I., Dmitriev A.A., Senchenko V.N. et al. Tumor suppressor function of the SEMA3B gene in human lung and renal cancers. PLos One 2015;10(5):e0123369. DOI:10.1371/journal.pone.0123369. PMID: 25961819.; Береснева Е.В., Рыков С.В., Ходырев Д.С. и др. Профиль метилирования группы генов микроРНК при светлоклеточном почечноклеточном раке; связь с прогрессией рака. Генетика 2013;49(3):366—75. DOI:10.1134/S1022795413030034. PMID: 23755536.; Lee K.H., Lotterman C., Karikari C. et al. Epigenetic silencing of MicroRNA miR-107 regulates cyclindependent kinase 6 expression in pancreatic cancer. Pancreatology 2009;9(3):293—301. DOI:10.1159/000186051. PMID: 19407485.; Yang C., Cai J., Wang Q. et al. Epigenetic silencing of miR-130b in ovarian cancer promotes the development of multidrug resistance by targeting colony-stimulating factor 1. Gynecol Oncol 2012;124(2): 325—34. DOI:10.1016/j.ygyno.2011.10.013. PMID: 22005523.; Li H.P., Huang H.Y., Lai Y.R. et al. Silencing of miRNA-148a by hyper methylation activates the integrin-mediated signaling pathway in nasopharyngeal carcinoma. Oncotarget 2014;5(17):7610—24. DOI:10.18632/oncotarget.2282. PMID: 25277193.; Wang C., Hu J., Lu M. et al. A panel of five serum miRNAs as a potential diagnostic tool for early-stage renal cell carcinoma. Sci Rep 2015;5:7610. DOI:10.1038/srep07610. PMID: 25556603.; Yadav S., Khandelwal M., Seth A. et al. Serum microRNA expression profiling: potential diagnostic implications of a panel of serum microRNAs for clear cell renal cell cancer. Urology 2017;104:64—9. DOI:10.1016/j.urology.2017.03.013. PMID: 28336290.; Wykoff C.C., Beasley N.J., Watson P.H. et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 2000;60:7075—83. PMID: 11156414.; Meng Q., Xiang L., Fu J. et al. Transcriptome profiling reveals miR-9-3p as a novel tumor suppressor in gastric cancer. Oncotarget 2017;6(8/23):37321—31. DOI:10.18632/oncotarget.16310. PMID: 28418879.; Пронина И.В., Климов Е.А., Бурденный А.М. и др. Метилирование генов микроРНК miR-129-2, miR-9-1, изменение их экспрессии и активация генов потенциальных мишеней этих микроРНК при раке почки. Молекулярная биология 2017;51(1):73—84. DOI:10.7868/S0026898416060161.; Cao H., Liu Z., Wang R. et al. miR-148a suppresses human renal cell carcinoma malignancy by targeting AKT2. Oncol Rep 2017;37(1):147—54. DOI:10.3892/or.2016.5257. PMID: 27878305.; Varachev V., Loginov V., Pronina I. et al. Hypermethylated tumor suppressor microRNAs as novel markers of clear cell renal cell carcinoma. FEBS Open Bio 2018;8(1):304—5. DOI:10.1002/2211-5463.12453.; Marconi L., Dabestani S., Lam T.B. et al. Systematic review and meta-analysis of diagnostic accuracy of percutaneous renal tumour biopsy. Eur Urol 2016;69:660—73. DOI:10.1016/j.eururo.2016.04.027. PMID: 27157997.; https://oncourology.abvpress.ru/oncur/article/view/886

الاتاحة: https://oncourology.abvpress.ru/oncur/article/view/886
https://doi.org/10.17650/1726-9776-2018-14-4-16-21

المؤلفون: A. Kirichek A., B. Kamolov Sh., N. Savyolov A., V. Matveev B., А. Киричек А., Б. Камолов Ш., Н. Савёлов А., В. Матвеев Б.

المصدر: Cancer Urology; Том 14, № 1 (2018); 166-172 ; Онкоурология; Том 14, № 1 (2018); 166-172 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2018-14-1

مصطلحات موضوعية: TNM classification, staging, evidence level, micrometastasis of prostate cancer, predictive model, World Health Organization classification, TNM-классификация, стадирование, уровень доказательности, микрометастаз рака предстательной железы, предикторная модель, классификация Всемирной организации здравоохранения

وصف الملف: application/pdf

Relation: https://oncourology.abvpress.ru/oncur/article/view/800/748; Amin M.B., Greene F.L., Edge S.B. et al. The eighth edition AJCC cancer staging manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin 2017;67(2):93–9. DOI:10.3322/caac.21388. PMID: 28094848.; Kattan M.W., Hess K.R., Amin M.B. et al. American Joint Committee on Cancer acceptance criteria for inclusion of risk models for individualized prognosis in the practice of precision medicine. CA Cancer J Clin 2016;66(5):370–4. DOI:10.3322/caac.21339. PMID: 26784705.; Brierley J.D., Gospodarowicz M.K., Wittekind C. TNM classification of malignant tumours. 8th edn. Oxford, UK: Wiley Blackwell, 2017.; Epstein J.I., Egevad L., Amin M.B. et al. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: definition of grading patterns and proposal for a new grading system. Am J Surg Pathol 2016;40(2):244–52. DOI:10.1097/PAS.0000000000000530. PMID: 26492179.; Epstein J.I., Amin M.B., Reuter V.E., Humphrey P.A. Contemporary Gleason grading of prostatic carcinoma: an update with discussion on practical issues to implement the 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 2017;41(4):e1–7. DOI:10.1097/PAS.0000000000000820. PMID: 28177964.; Epstein J.I., Zelefsky M.J., Sjoberg D.D. et al. A contemporary prostate cancer grading system: a validated alternative to the Gleason score. Eur Urol 2016;69(3):428–35. DOI:10.1016/j.eururo.2015.06.046. PMID: 26166626.; Moch H., Humphrey P.A., Ulbright T.M., Reuter V.E. WHO Classification of Tumours of the Urinary System and Male Genital Organs. Geneva, Switzerland: WHO Press, 2016.; Sanda M.G., Chen R.C., Crispino T. et al. Clinically localized prostate cancer: AUA/ ASTRO/SUO Guideline, 2017. Available at: http://www.auanet.org/guidelines/clinically-localized-prostate-cancer-new-(aua/astro/suo-guideline-2017).; NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Published February 21, 2017. Available at: https://www.nccn.org/professionals/physician_gls/f_guidelines.asp.; Kordan Y., Chang S.S., Salem S. et al. Pathological stage T2 subgroups to predict biochemical recurrence after prostatectomy. J Urol 2009;182(5):2291–5. DOI:10.1016/j.juro.2009.07.020. PMID: 19758638.; Chun F.K., Briganti A., Lebeau T. et al. The 2002 AJCC pT2 substages confer no prognostic information on the rate of biochemical recurrence after radical prostatectomy. Eur Urol 2006;49(2):273–8. DOI:10.1016/j.eururo.2005.12.009. PMID: 16413103.; Epstein J.I. Prognostic significance of tumor volume in radical prostatectomy and needle biopsy specimens. J Urol 2011;186(3): 790–7. DOI:10.1016/j.juro.2011.02.2695. PMID: 21788055.; van der Kwast T.H., Amin M.B., Billis A. et al. International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 2: T2 substaging and prostate cancer volume. Mod Pathol 2011;24(1):16–25. DOI:10.1038/modpathol.2010.156. PMID: 20818340.; Ettel M., Kong M., Lee P. et al. Modification of the pT2 substage classification in prostate adenocarcinoma. Hum Pathol 2016;56:57–63. DOI:10.1016/j.humpath.2016.05.016. PMID: 27251951.; Buyyounouski M.K., Choyke P.L., McKenney J.K. et al. Prostate cancer – major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin 2017;67(3): 245–53. DOI:10.3322/caac.21391. PMID: 28222223.; Bhindi B., Karnes R.J., Rangel L.J. et al. Independent validation of the American Joint Committee on Cancer 8th edition prostate cancer staging classification. J Urol 2017;198(6):1286–94. DOI:10.1016/j. juro.2017.06.085. PMID: 28669765.; Halabi S., Lin C.Y., Kelly W.K. et al. Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2014;32(7):671–7. DOI:10.1200/JCO.2013.52.3696. PMID: 24449231.; Halabi S., Lin C.Y., Small E.J. et al. Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapy. J Natl Cancer Inst 2013;105(22):1729–37. DOI:10.1093/jnci/djt280. PMID: 24136890.; Delahunt B., Cheville J.C., Martignoni G. et al. The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. Am J Surg Pathol 2013;37(10):1490–504. DOI:10.1097/PAS.0b013e318299f0fb. PMID: 24025520.; Przybycin C.G., McKenney J.K., Reynolds J.P. et al. Rhabdoid differentiation is associated with aggressive behavior in renal cell carcinoma: a clinicopathologic analysis of 76 cases with clinical follow-up. Am J Surg Pathol 2014;38(9):1260–5. DOI:10.1097/PAS.0000000000000251. PMID: 25127094.; Михайленко Д.С., Телешова М.В., Перепечин Д.В. и др. Герминальные нонсенсмутации в гене SMARCB1 у российских пациентов с рабдоидными опухолями почек. Онкоурология 2017;13(2):14–9. DOI:10.17650/1726-9776-2017-13-2-14-19.; Leivo M.Z., Sahoo D., Hamilton Z. et al. Analysis of T1 bladder cancer on biopsy and transurethral resection specimens: comparison and ranking of T1 quantification approaches to predict progression to muscularis propria invasion. Am J Surg Pathol 2018;42(1):e1–10. DOI:10.1097/PAS.0000000000000964. PMID: 29076872.; Babjuk M., Bohle A., Burger M. et al. EAU Guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol 2017;71:447–61. DOI:10.1016/j.eururo.2016.05.041.; Knoedler J.J., Boorjian S.A., Tollefson M.K. et al. Urothelial carcinoma involving the prostate: the association of revised tumour stage and coexistent bladder cancer with survival after radical cystectomy. BJU Int 2014;114(6):832–6. DOI:10.1111/bju.12486. PMID: 24119219.; Patel A.R., Cohn J.A., Abd El Latif A. et al. Validation of new AJCC exclusion criteria for subepithelial prostatic stromal invasion from pT4a bladder urothelial carcinoma. J Urol 2013;189:53–8. DOI:10.1016/j.juro.2012.09.006. PMID: 23164389.; Hu B., Satkunasivam R., Schuckman A. et al. Urothelial carcinoma in bladder diverticula: outcomes after radical cystectomy. World J Urol 2015;33(10):1397–402. DOI:10.1007/ s00345-014-1472-5. PMID: 25549760.; Bella A.J., Stitt L.W., Chin J.L., Izawa J.I. The prognostic significance of metastatic perivesical lymph nodes identified in radical cystectomy specimens for transitional cell carcinoma of the bladder. J Urol 2003; 170(6 Pt 1):2253–7. DOI:10.1097/01.ju.0000095804.33714.ea. PMID: 14634391.; Galsky M.D., Moshier E., Krege S. et al. Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy. Cancer 2013;119(16):3012–9. DOI:10.1002/cncr.28146. PMID: 23720216.; Verrill C., Yilmaz A., Srigley J.R. et al. Reporting and staging of testicular germ cell tumors: the International Society of Urological Pathology (ISUP) testicular cancer consultation conference recommendations. Am J Surg Pathol 2017;41(6):e22–32. DOI:10.1097/PAS.0000000000000844. PMID: 28368923.; Williamson S.R., Delahunt B., Magi-Galluzzi C. et al. The World Health Organization 2016 classification of testicular germ cell tumours: a review and update from the International Society of Urological Pathology Testis Consultation Panel. Histopathology 2017;70(3):335–46. DOI:10.1111/his.13102. PMID: 27747907.; Chung P., Daugaard G., Tyldesley S. et al. Evaluation of a prognostic model for risk of relapse in stage I seminoma surveillance. Cancer Med 2015;4(1):155–60. DOI:10.1002/cam4.324. PMID: 25236854.; Yilmaz A., Cheng T., Zhang J., Trpkov K. Testicular hilum and vascular invasion predict advanced clinical stage in nonseminomatous germ cell tumors. Mod Pathol 2013;26:579–86. DOI:10.1038/modpathol.2012.189. PMID: 23238629.; Aparicio J., Maroto P., Garcia del Muro X. et al. Prognostic factors for relapse in stage I seminoma: a new nomogram derived from three consecutive, risk-adapted studies from the Spanish Germ Cell Cancer Group (SGCCG). Ann Oncol 2014;25:2173–8. DOI:10.1093/annonc/mdu437. PMID: 25210015.; Kamba T., Kamoto T., Okubo K. et al. Outcome of different post-orchiectomy management for stage I seminoma: Japanese multiinstitutional study including 425 patients. Int J Urol 2010;17(12):980–7. DOI:10.1111/j.1442-2042.2010.02645.x. PMID: 20955354.; Sun M., Djajadiningrat R.S., Alnajjar H.M. et al. Development and external validation of a prognostic tool for prediction of cancerspecific mortality after complete loco-regional pathological staging for squamous cell carcinoma of the penis. BJU Int 2015;116:734–43. DOI:10.1111/bju.12677. PMID: 24552303.; Velazquez E.F., Ayala G., Liu H. et al. Histologic grade and perineural invasion are more important than tumor thickness as predictor of nodal metastasis in penile squamous cell carcinoma invading 5 to 10 mm. Am J Surg Pathol 2008;32(7):974–9. DOI:10.1097/PAS.0b013e3181641365. PMID: 18460979.; Li Z.S., Yao K., Chen P. et al. Modification of N staging systems for penile cancer: a more precise prediction of prognosis. Br J Cancer 2015;113(12):1746. DOI:10.1038/bjc.2015.457. PMID: 26695555.; Hakenberg O.W., Comperat E.M., Minhas S. et al. EAU guidelines on penile cancer: 2014 update. Eur Urol 2015;67(1):142–50. DOI:10.1016/j.eururo.2014.10.017. PMID: 25457021.; Li Z., Guo S., Wu Z. et al. Subclassification of pN3 staging systems for penile cancer: proposal for modification of the current TNM classification. Urol Oncol 2017;35(9):543. DOI:10.1016/j.urolonc.2017.04.009. PMID: 28578871.; https://oncourology.abvpress.ru/oncur/article/view/800

الاتاحة: https://oncourology.abvpress.ru/oncur/article/view/800
https://doi.org/10.17650/1726-9776-2018-14-1-166-172

المؤلفون: A. Kirichek A., B. Kamolov Sh., V. Matveev B., А. Киричек А., Б. Камолов Ш., В. Матвеев Б.

المصدر: Cancer Urology; Том 13, № 4 (2017); 133-140 ; Онкоурология; Том 13, № 4 (2017); 133-140 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2017-13-4

مصطلحات موضوعية: deferred cytoreductive nephrectomy, sequential targeted therapy, combination immunotherapy with nivolumab and ipilimumab, cabozantinib, lenvatinib in combination with pembrolizumab, monoclonal antibody VEGFR-2 antagonist, ramucirumab, whole exome sequencing of tumor DNA, tumor mutation burden, отложенная циторедуктивная нефрэктомия, последовательная таргетная терапия, комбинированная иммунотерапия ниволумабом и ипилимумабом, кабозантиниб, комбинация ленватиниба и пембролизумаба, моноклональное антитело к рецептору 2-го типа эндотелиального фактора роста сосудов, рамуцирумаб, полноэкзомное секвенирование опухолевой ДНК, мутационная нагрузка

وصف الملف: application/pdf

Relation: https://oncourology.abvpress.ru/oncur/article/view/779/728; https://oncourology.abvpress.ru/oncur/article/view/779

الاتاحة: https://oncourology.abvpress.ru/oncur/article/view/779
https://doi.org/10.17650/1726-9776-2017-13-4-133-140

المؤلفون: Ph. Kossov A., B. Kamolov Sh., I. Abdullin I., E. Baranova O., M. Shorikov A., V. Panov O., I. Turin E., V. Matveev B., N. Grigor’ev A., B. Dolgushin I., Ф. Коссов А., Б. Камолов Ш., И. Абдуллин И., Е. Баранова О., М. Шориков А., В. Панов О., И. Тюрин Е., В. Матвеев Б., Н. Григорьев А., Б. Долгушин И.

المصدر: Cancer Urology; Том 13, № 3 (2017); 61-70 ; Онкоурология; Том 13, № 3 (2017); 61-70 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2017-13-3

مصطلحات موضوعية: prostate cancer, MRI/ultrasound fusion prostate biopsy, multiparametric magnetic resonance imaging, standard prostate biopsy, clinically significant prostate cancer, рак предстательной железы, МРТ/УЗИ fusion-биопсия предстательной железы, мультипараметрическая магнитно-резонансная томография, стандартная биопсия предстательной железы, клинически значимый рак предстательной железы

وصف الملف: application/pdf

Relation: https://oncourology.abvpress.ru/oncur/article/view/700/700; Scattoni V., Maccagnano C., Capitanio U. et al. Random biopsy: when, how many and where to take the cores? World J Urol 2014;32(4):859–69. DOI:10.1007/s00345-014-1335-0. PMID: 24908067.; Presti J. C. Prostate biopsy: how many cores are enough? Urol Oncol 2003;21(2):135–40. PMID: 12856642.; Bjurlin M. A., Wysock J. S., Taneja S. S. Optimization of prostate biopsy: review of technique and complications. Urol Clin North Am 2014;41(2):299–313. DOI:10.1016/j.ucl.2014.01.011. PMID: 24725491.; Djavan B., Milani S., Remzi M. Prostate biopsy: who, how and when. An update. Can J Urol 2005;12(Suppl 1):44–8. PMID: 15780165.; Rodríguez-Covarrubias F., González-Ramírez A., Aguilar-Davidov B. et al. Extended sampling at first biopsy improves cancer detection rate: results of a prospective, randomized trial comparing 12 versus 18-core prostate biopsy. J Urol 2011;185(6):2132–6. DOI:10.1016/j.juro.2011.02.010. PMID: 21496851.; Ploussard G., Nicolaiew N., Marchand C. et al. Prospective evaluation of an extended 21- core biopsy scheme as initial prostate cancer diagnostic strategy. Eur Urol 2014;65(1):154–61. DOI:10.1016/j.eururo.2012.05.049. PMID: 22698576.; Weiner A. B., Patel S. G., Etzioni R. et al. National trends in the management of low and intermediate risk prostate cancer in the United States. J Urol 2015;193(1):95–102. DOI:10.1016/j.juro.2014.07.111. PMID: 25106900.; Pokorny M. R., De Rooij M., Duncan E. et al. Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies. Eur Urol 2014;66(1):22–9. DOI:10.1016/j.eururo.2014.03.002. PMID: 24666839.; Sonn G. A., Chang E., Natarajan S. et al. Value of targeted prostate biopsy using magnetic resonance-ultrasound fusion in men with prior negative biopsy and elevated prostate- specific antigen. Eur Urol 2014;65(4):809–15. DOI:10.1016/j.eururo.2013.03.025. PMID: 23523537.; Weinreb J. C., Barentsz J. O., Choyke P. L. et al. PI-RADS prostate imaging – reporting and data system: 2015, version 2. Eur Urol 2016;69(1):16–40. DOI:10.1016/j.eururo.2015.08.052. PMID: 26427566.; Barentsz J. O., Richenberg J., Clements R. et al. ESUR prostate MR guidelines 2012. Eur Radiol 2012;22(4):746–57. DOI:10.1007/s00330-011-2377-y. PMID: 22322308.; Somford D. M., Hamoen E. H., Fütterer J. J. et al. The predictive value of endorectal 3 Tesla multiparametric magnetic resonance imaging for extraprostatic extension in patients with low, intermediate and high risk prostate cancer. J Urol 2013;190(5): 1728–34. DOI:10.1016/j.juro.2013.05.021. PMID: 23680307.; Delongchamps N. B., Zerbib M. Role of magnetic resonance imaging before initial biopsy: comparison of magnetic resonance imaging-targeted and systematic biopsy for significant prostate cancer detection. Eur Urol 2012;61(3):622–3. DOI:10.1016/j.eururo.2011.12.038. PMID: 22289974.; Hoeks C. M., Schouten M. G., Bomers J. G. et al. Three-tesla magnetic resonance-guided prostate biopsy in men with increased prostate-specific antigen and repeated, negative, random, systematic, transrectal ultrasound biopsies: detection of clinically significant prostate cancers. Eur Urol 2012;62(5):902–9. DOI:10.1016/j.eururo.2012.01.047. PMID: 22325447.; Rosenkrantz A. B., Verma S., Choyke P. et al. Prostate magnetic resonance imaging and magnetic resonance imaging targeted biopsy in patients with a prior negative biopsy: a consensus statement by AUA and SAR. J Urol 2016;196(6):1613–8. DOI:10.1016/j.juro.2016.06.079. PMID: 27320841.; Cash H., Maxeiner A., Stephan C. et al. The detection of significant prostate cancer is correlated with the Prostate Imaging Reporting and Data System (PI-RADS) in MRI/transrectal ultrasound fusion biopsy. World J Urol 2016;34(4): 525–32. DOI:10.1007/s00345-015-1671-8. PMID: 26293117.; https://oncourology.abvpress.ru/oncur/article/view/700

الاتاحة: https://oncourology.abvpress.ru/oncur/article/view/700
https://doi.org/10.17650/1726-9776-2017-13-3-61-70

المؤلفون: N. Apanovich V., M. Peters V., A. Korotaeva A., P. Apanovich V., A. Markova S., B. Kamolov Sh., V. Matveev B., A. Karpukhin V., Н. Апанович В., М. Петерс В., А. Коротаева А., П. Апанович В., А. Маркова С., Б. Камолов Ш., В. Матвеев Б., А. Карпухин В.

المصدر: Cancer Urology; Том 12, № 4 (2016); 16-20 ; Онкоурология; Том 12, № 4 (2016); 16-20 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2016-12-4

مصطلحات موضوعية: clear cell renal cell carcinoma, molecular genetic diagnostics, differential gene expression, светлоклеточный почечно-клеточный рак, молекулярно-генетическая диагностика, дифференциальная экспрессия генов

وصف الملف: application/pdf

Relation: https://oncourology.abvpress.ru/oncur/article/view/602/616; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/602/334; https://oncourology.abvpress.ru/oncur/article/downloadSuppFile/602/335; Статистика злокачественных новообразований в России и странах СНГ в 2012 г. Под ред. М.И. Давыдова, Е.М. Аксель. М.: Издательская группа РОНЦ, 2014. 226 с. [Statistics of malignant tumors in Russia and CIS countries in 2012. Eds. by: М.I. Davydov, Е.М. Аksel’. Мoscow: Izdatel’skaya gruppa RONTS, 2014. 226 p. (In Russ.)].; Ljungberg B., Bensalah K., Bex A. et al. Guidelines on renal cell carcinoma. European association of urology, 2014. 70 p.; Caoili E.M., Davenport M.S. Role of percutaneous needle biopsy for renal masses. Semin Intervent Radiol 2014;31(1):20–6. DOI:10.1055/s-0033-1363839. PMID: 24596436.; Vetterlein M.W., Jindal T., Becker A. et al. Small renal masses in the elderly: Contemporary treatment approaches and comparative oncological outcomes of nonsurgical and surgical strategies. Investig Clin Urol 2016;57(4):231–9. DOI:10.4111/icu.2016.57.4.231. PMID: 27437532.; Marconi L., Dabestani S., Lam T.B. et al. systematic review and meta-analysis of diagnostic accuracy of percutaneous renal tumour biopsy. Eur Urol 2016;69(4):660–73. DOI:10.1016/j.eururo.2015.07.072. PMID: 26323946.; Tostain J., Li G., Gentil-Perret A., Gigante M. Carbonic anhydrase 9 in clear cell renal cell carcinoma: a marker for diagnosis, prognosis and treatment. Eur J Cancer 2010;46(18):3141–8. DOI:10.1016/j.ejca.2010.07.020. PMID: 20709527.; Luo W., Hu H., Chang R. et al. Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1. Cell 2011;145(5):732–44. DOI:10.1016/j.cell.2011.03.054. PMID: 21620138.; Gimm T., Wiese M., Teschemacher B. et al. Hypoxia-inducible protein 2 is a novel lipid droplet protein and a specific target gene of hypoxia-inducible factor-1 FASEB 2010;24(11):4443–58. DOI:10.1096/fj.10-159806. PMID: 20624928.; Seo T., Konda R., Sugimura J. et al. Expression of hypoxia-inducible protein 2 in renal cell carcinoma: a promising candidate for molecular targeting therapy. Oncol Lett 2010;1(4):697–701. DOI:10.3892/ol_00000122. PMID: 22966366.; Fredlund E., Ovenberger M., Borg K., Påhlman S. Transcriptional adaptation of neuroblastoma cells to hypoxia. Biochem Biophys Res Commun 2008;366(4):1054–60. DOI:10.1016/j.bbrc.2007.12.074. PMID: 18155155.; Apanovich N.V., Poyarkov S.V., Peters M.V. et al. The differential gene expression in clear cell renal cell carcinoma and biomarker development. Eur Hum Gen 2015;23(Suppl 1):446.; Minton D.R., Fu L., Mongan N.P. et al. Role of NADH Dehydrogenase (Ubiquinone) 1 Alpha Subcomplex 4-Like 2 in Clear Cell Renal Cell Carcinoma. Clin Cancer Res 2016;22(11):2791–801. DOI:10.1158/1078-0432.CCR-15-1511. PMID: 26783287.; Law A.Y., Wong C.K. Stanniocalcin-2 promotes epithelial-mesenchymal transition and invasiveness in hypoxic human ovarian cancer cells. Exp Cell Res 2010;316(20):3425–34. DOI:10.1016/j.yexcr.2010.06.026. PMID: 20619259.; Yeung B.H., Law A.Y., Wong C.K. Evolution and roles of stanniocalcin. Mol Cell Endocrinol 2012;349(2):272–80. DOI:10.1016/j.mce.2011.11.007. PMID: 22115958.; Fisher K.E., Yin-Goen Q., Alexis D. et al. Gene expression profiling of clear cell papillary renal cell carcinoma: comparison with clear cell renal cell carcinoma and papillary renal cell carcinoma. Mod Pathol 2014;27(2)222–30. DOI:10.1038/modpathol.2013.140. PMID: 23887297.; Li G., Bilal I., Gentil-Perret A. et al. CA9 as a molecular marker for differential diagnosis of cystic renal tumors. Urol Oncol 2012;30(4):463–8. DOI:10.1016/j.urolonc.2010.04.014. PMID: 20822935.; Girgis A.H., Iakovlev V.V., Beheshti B. et al. Multilevel whole-genome analysis reveals candidate biomarkers in clear cell renal cell carcinoma. Cancer Res 2012;72(20):273–84. DOI:10.1158/0008-5472.CAN-12-0656. PMID: 22926558.; The Principles of Clinical Cytogenetics Eds. by: S.L. Gersen, M.B. Keagle. NY: Springer, 2013. Рp. 380–381.; Davis C.F., Ricketts C.J., Wang M. et al. The somatic genomic landscape of chromophobe renal cell carcinoma. Cancer Cell 2014;26(3):319–30. DOI:10.1016/j.ccr.2014.07.014. PMID: 25155756.; https://oncourology.abvpress.ru/oncur/article/view/602

الاتاحة: https://oncourology.abvpress.ru/oncur/article/view/602
https://doi.org/10.17650/1726-9776-2016-12-4-16-20

المؤلفون: B. Alekseev Ya., V. Matveev B., I. Rusakov G., M. Volkova I., O. Karjakin B., L. Bolotina V., G. Kolesnikov P., E. Kopylcov I., B. Kamolov Sh., K. Nyushkov M., V. Atduev A., P. Karnauch A., R. Smirnov V., O. Tonacheva G., D. Tevs V., A. Izmailov A., A. Govorov V., R. Gafanov A., S. Mishugin V., A. Karyakin O., Б. Алексеев Я., В. Матвеев Б., И. Русаков Г., М. Волкова И., О. Карякин Б., Л. Болотина В., Г. Колесников П., Е. Копыльцов И., Б. Камолов Ш., К. Нюшко М., В. Атдуев А., П. Карнаух А., Р. Смирнов В., О. Тоначева Г., Д. Тевс В., А. Измайлов А., А. Говоров В., Р. Гафанов А., С. Мишугин В., А. Карякин О.

المصدر: Cancer Urology; Том 12, № 3 (2016); 109-110 ; Онкоурология; Том 12, № 3 (2016); 109-110 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2016-12-3

وصف الملف: application/pdf

Relation: https://oncourology.abvpress.ru/oncur/article/view/616/585; Злокачественные новообразования в России в 2014 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М., 2016.; Состояние онкологической помощи населению России в 2014 году. Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М., 2015.; Ryan C.J., Tindall D.J. Androgen receptor rediscovered: The new biology and targeting the androgen receptor therapeutically. J Clin Oncol 2011;29(27):3651–8.; Kirby M., Hirst C., Crawford E.D. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract 2011;65(11):1180–92.; Scher H.I., Fizazi K., Saad F. et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367(13):1187–91.; Beer T.M., Armstrong A.J., Rathkopf D.E. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014;371(5):424–33.; Yap T.A., Zivi A., Omlin A., de Bono J.S. The changing therapeutic landscape of castration-resistant prostate cancer. Nat Rev Clin Oncol 2011;8(10): 597–610.; Beltran H., Beer T.M., Carducci M.A. et al. New therapies for castrationresistant prostate cancer: efficacy and safety. Eur Urol 2011;60(2): 279–90.; https://oncourology.abvpress.ru/oncur/article/view/616

الاتاحة: https://oncourology.abvpress.ru/oncur/article/view/616
https://doi.org/10.17650/1726-9776-2016-12-3-109-110

المؤلفون: G. Akhverdiyeva I., V. Panov О., I. Tyurin Е., B. Dolgushin I., V. Matveyev B., B. Kamolov Sh., Е. Tarachkova V., P. Bulychkin V., Г. Ахвердиева И., В. Панов О., И. Тюрин Е., Б. Долгушин И., В. Матвеев Б., Б. Камолов Ш., Е. Тарачкова В., П. Булычкин В.

المصدر: Cancer Urology; Том 11, № 4 (2015); 72-80 ; Онкоурология; Том 11, № 4 (2015); 72-80 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2015-11-4

مصطلحات موضوعية: prostate cancer, multiparametric magnetic resonance imaging, prostate- specific antigen, salvage radiation therapy, рак предстательной железы, мультипараметрическая магнитно-резонансная томография, простатспецифический антиген, спасительная лучевая терапия

وصف الملف: application/pdf

Relation: https://oncourology.abvpress.ru/oncur/article/view/477/494; Alan J. Wein, Louis R. Kavoussi, Andrew C. Novick et al. Campbell’s urology. Vol. 4, 8 edn. Philadelphia: Saunders, 2002.; Заболеваемость злокачественными новообразованиями в России в 2013 году. Под ред. А.Д. Каприна, В.В.Старинского. М., 2014. [Incidence of malignant neoplasms in Russia in 2013. Under the editorship of Kaprin А.D., Starinskiy V.V., Moscow, 2014. (In Russ.)].; DeSantis C., Siegel R., Jemal A. American Cancer Society. Cancer Facts and Figures 2008. Atlanta: American Cancer Society, 2008.; Joniau S., Hsu C.Y., Lerut E. et al. A pretreatment table for the prediction of final histopathology after radical prostatectomy in clinical unilateral T3a prostate cancer. Eur Urol 2007;51(2): 388–94.; Makarov D.V., Trock B.J., Humphreys E.B. et al. Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology 2007;69(6):1095–101.; Клиническая онкоурология. М.: ИД «АБВ-пресс», 2003. [Klinicheskaya oncourologiya = Clinical oncourology. Moscow: Publishing house «ABV-press», 2003. (In Russ.)].; Карякин О.Б. Лечение рецидивов рака предстательной железы после радикальной простатэктомии и дистанционной лучевой терапии. М.: АБВ-пресс, 2011. [Karyakin О.B. Treatment opions for recurrent prostate cancer after radical prostatectomy and distant radiation therapy. Мoscow: Publishing house «ABV-press», 2011. (In Russ.)].; Cookson M.S., Aus G., Burnett A.L. et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol 2007;177(2):540–5.; Mueller-Lisse U.G., Swanson M.G., Vigneron D.B., Kurhanewicz J. Magnetic resonance spectroscopy in patients with locally confined prostate cancer: association of prostatic citrate and metabolic atrophy with time on hormone deprivation therapy, PSA level, and biopsy Gleason score. Eur Radiol 2007; 17(2):371–8.; Волобуев А.И., Иванова Л.А., Кулабухова Е.А. Руководство по лучевой диагностике в гинекологии. СПб.: ЭЛБИ-СПб, 2008. [Volobuyev А.I., Ivanova L.A., Kulabukhova Е.А. Guidelines for diagnostic radiology in gynecology. Saint Petersburg: ELBI-SPb, 2008. (In Russ.)].; Fuchsjager M., Akin O., Shukla-Dave A. et al. The role of MRI and MRSI in diagnosis, treatment selection, and post-treatment follow-up for prostate cancer. Clin Adv Hematol Oncol 2009;7(3):193–202.; Мищенко А.В., Дубицкий Д.Л., Москаленко Е.А. Возможности магнитно-резонансной спектроскопии в диагностике аденокарциномы предстательной железы. Лучевая диагностика и терапия 2010;4(1):62–7. [Mischenko А.V., Dubitskiy D.L., Moskalenko Е.А. Value of magnetic resonance spectroscopic imaging in the diagnosis of prostate cancer. Luchevaya diagnostika i terapiya = Diagnostic and therapeutic radiology 2010;4(1):62–7. (In Russ.)].; Mullerad M., Kastin A., Adusumilli P.S. et al. Comparison of nephron-sparing surgery in central versus peripheral renal tumors. Urology 2005;65(3):467–72.; D'Amico A.V., Whittington R., Schnall M. et al. The impact of the inclusion of endorectal coil magnetic resonance imaging in a multivariate analysis to predict clinically unsuspected extraprostatic cancer. Cancer 1995;75(9):2368–72.; Jager G.J., Ruijter E.T., van de Kaa C.A. et al. Local staging of prostate cancer with endorectal MR imaging: correlation with histopathology. AJR 1996;166(4):845–52.; Рубцова Н.А., Алексеев Б.Я., Мамонтова И.С. и др. Возможности МРТ в диагностике локализованной формы рака предстательной железы. Медицинская визуализация 2014;(1):124–6. [Rubtsova N.А., Alekseyev B.Ya., Mamontova I.S. et al. Role of MRI in the diagnosis of localized prostate cancer. Meditsinskaya vizualizatsiya = Medical imaging 2014;(1):124–6. (In Russ.)].; Carlani M., Mancino S., Bonanno E. et al. Combined morphological, [1H]-MR spectroscopic and contrast-enhanced imaging of human prostate cancer with a 3-Tesla scanner: preliminary experience. La Radiologia medica 2008;113(5):670–88.; Ахвердиева Г.И., Санай Э.Б., Панов В.О. и др. Роль мультипараметрической МРТ в выявлении и локализации ранннего рака предстательной железы. Онкоурология 2013;(4):25–36. [Akhverdiyeva G.I., Sanay E.B., Panov V.О. et al. Role of multiparametric MRI in the detection and localization of early-stage prostate cancer. Onkourologiya = Oncourology 2013;(4): 25–36. (In Russ.)].; Castillo M., Smith J.K., Kwock L., Wilber K. Apparent diffusion coefficients in the evaluation of high-grade cerebral gliomas. AJNR 2001;22(1):60–4.; Eis M., Els T., Hoehn-Berlage M. High resolution quantitative relaxation and diffusion MRI of three different experimental brain tumors in rat. Magnetic resonance in medicine 1995;34(6):835–44.; Eis M., Els T., Hoehn-Berlage M., Hossmann K.A. Quantitative diffusion MR imaging of cerebral tumor and edema. Acta neurochir Suppl 1994, 60: 344–6.; Sugahara T., Korogi Y., Kochi M. et al. Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas. JMRI 1999;9(1): 53–60.; Tien R.D., Felsberg G.J., Friedman H. et al. MR imaging of high-grade cerebral gliomas: value of diffusion-weighted echoplanar pulse sequences. AJR 1994;162(3):671–7.; Shimofusa R., Fujimoto H., Akamata H. et al. Diffusion-weighted imaging of prostate cancer. J Comp Assist Tomogr 2005;29(2):149–53.; Ocak I., Bernardo M., Metzger G. et al. Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters. AJR 2007;89(4):849.; Brawer M.K., Deering R.E., Brown M. et al. Predictors of pathologic stage in prostatic carcinoma. The role of neovascularity. Cancer 1994;73(3): 678–87.; Siegal J.A., Yu E., Brawer M.K. Topography of neovascularity in human prostate carcinoma. Cancer 1995;75(10): 2545–51.; Weidner N., Carroll P.R., Flax J. et al. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993;143(2):401–9.; Delorme S., Knopp M.V. Non-invasive vascular imaging: assessing tumour vascularity. Eur Radiol 1998;(4):517–27.; Sakai I., Harada K., Kurahashi T. et al. Usefulness of the nadir value of serum prostatespecific antigen measured by an ultrasensitive assay as a predictor of biochemical recurrence after radical prostatectomy for clinically localized prostate cancer. Urol Int 2006;6(3):227–31.; Casciani E., Polettini E., Carmenini E. et al. Endorectal and dynamic contrastenhanced MRI for detection of local recurrence after radical prostatectomy. AJR 2008;90(5):1187–92.; Cirillo S., Petracchini M., Scotti L. et al. Endorectal magnetic resonance imaging at 1.5 Tesla to assess local recurrence following radical prostatectomy using T2-weighted and contrast-enhanced imaging. Eur Radiol 2009;9(3):761–9.; Китаев С.В. Диагностические возможности магнитно-резонансной томографии с использованием катушки для тела в определении стадии рака предстательной железы. Онкоурология 2008;(4):25–29. [Kitayev S.V. Diagnostic possibilities of magnetic resonance imaging body coil in the determining of prostate cancer stage. Onkourologiya = Oncourology 2008;(4): 25–29. (In Russ.)].; Мухомор А.И., Ахвердиева Г.И., Санай Э.Б. и др. Комплексное трансректальное ультразвуковое исследование с цветовым допплеровским кодированием, допплерографией и соноэластографией в выявлении рака предстательной железы. Онкоурология 2013;(2):42–52. [Mukhomor А.I., Akhverdiyeva G.I., Sanay E.B. et al. Complex transrectal ultrasound with color flow mapping,Doppler sonography and sonoelastography in prostate cancer evaluation. Onkourologiya = Oncourology 2013;(2):42–52. (In Russ.)].; Ткачев С.И., Булычкин П.В., Бердник А.В. и др. Гипофракционированная «спасительная» лучевая терапия больных с рецидивами рака предстательной железы после радикальной простатэктомии. Медицинская радиология и радиационная безопасность 2014;(6):43–8. [Tkachev S.I., Bulychkin P.V., Berdnik А.V. et al. Hypofractionated salvage radiotherapy for recurrence prostate cancer after radical prostatectomy. Meditsinskaya radiologiya i radiatsionnaya bezopasnost = Medical radology and radiation safety 2014;(6):43–8. (In Russ.)].; https://oncourology.abvpress.ru/oncur/article/view/477

الاتاحة: https://oncourology.abvpress.ru/oncur/article/view/477
https://doi.org/10.17650/1726-9776-2015-11-4-72-80

المؤلفون: A. Markova S., S. Polikarpova B., B. Kamolov Sh., Ya. Gridneva V., S. Kalinin A., M. Peters V., V. Matveev B., А. Маркова С., С. Поликарпова Б., Б. Камолов Ш., Я. Гриднева В., С. Калинин А., М. Петерс В., В. Матвеев Б.

المصدر: Cancer Urology; Том 11, № 2 (2015); 77-84 ; Онкоурология; Том 11, № 2 (2015); 77-84 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2015-11-2

مصطلحات موضوعية: castration-resistant prostate cancer, docetacel, abiraterone acetate, cabazitaxel, overall survival, predictors, alkaline phosphatase, prostate-specific antigen, hemoglobin, lactate dehydrogenase, calcium, ECOG scale, кастрационно-резистентный рак предстательной железы, доцетаксел, абиратерона ацетат, кабазитаксел, общая выживаемость, факторы прогноза, щелочная фосфатаза, простатоспецифический антиген, гемоглобин, лактатдегидрогеназа, кальций, шкала ECOG

وصف الملف: application/pdf

Relation: https://oncourology.abvpress.ru/oncur/article/view/457/440; https://oncourology.abvpress.ru/oncur/article/view/457/482; Kirby M., Hirst C., Crawford E. D. Characterising the castration-resistant prostate cancer population: a systematic review». Int J Clin Pract 2011;65(11):1180–92.; Therasse P., Arbuck S. G., Eisenhauer E. A. et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92(3):205–16.; Mottet N., Bellmunt J., Briers E. et al. European Association of Urology (EAU) Guidelines. 2015, p. 90.; Sridhar S. S., Freedland S. J., Gleave M. E. et al. Castration-resistant prostate cancer: from new pathophysiology to new treatment. Eur Urol 2014;65:289–99.; Crawford E. D., Eisenberger M. A., McLoed D.G. et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989;321:419–24.; Dijkman G. A., Janknegt R. A., De Reijke T. H.M. et al. Long-term efficacy and safety of nilutamide plus castration in advanced stage prostate cancer, and the significance of early prostate specific antigen normalization. J Urol 1997;158:160–3.; Eisenberger M. A., Blumenstein B. A., Crawford E. D. et al. Bilateral orchiec tomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998;339: 1036–42.; Armstrong A. J., Garrett-Mayer E. S., Ou Yang Y. C. et al. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer (HRPC). Clin Cancer Res 2007;13: 6396–403.; Halabi S., Lin C. Y., Kelly W. K. et al. Updated prognostic model for predicting overall survival in first-line chemotherapy for patients with metastatic castrationresistant prostate cancer. J Clin Oncol 2014; 32(7):671–7.; Halabi S., Small E. J., Kantoff P. W. et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 2003;21(7):1232–7.; Nakabayashi M., Hayes J., Taplin M. Clinical predictors of survival in men with castration-resistant prostate cancer. Cancer 2013;119:2990–8.; Smaletz O., Scher H. I., Small E. J. et al. Nomogram for overall survival of patients with progressive metastatic prostate cancer after castration. J Clin Oncol 2002;20:3972–82.; de Bono J. S., Oudard S., Ozguroglu M. et al. Prednisone plus cabazitaxel or itoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010;376:1147–54.; Mulders P. F., Molina А., Marberger М. et al. Efficacy and safety of abiraterone acetate in an elderly patient subgroup (aged 75 and older) with metastatic castration resistant prostate cancer after docetaxel-based chemotherapy. Eur Urol 2014;65:875–83.; Leibowitz-Amit R., Templeton A. J., Alibhai Sh. M. et al. Efficacy and toxicity of abiraterone and docetaxel in octogenarians with metastatic castration-resistant prostate cancer. J Geriatr Oncol 2015;6:23–8.; de Bono J. S., Oudard S., Ozguroglu M. et al. TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castrationresistant prostate cancer progressing after docetaxel treatment: a randomised openlabel trial. Lancet 2010;376:1147–54.; Albertsen P. C., Hanley J. A., Barrows G. H. et al. Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst 2005;97:1248–53.; D, elia C., Cerruto M. A., Cioffi A. et al. Upgrading and upstaging in prostate cancer: From prostate biopsy to radical prostatectomy. Mol Clin Oncol 2014;(6):1145–9.; Kvale R., Moller B., Wahlqvist R. et al. Concordance between Gleason scores of needle biopsies and radical prostatectomy specimens: a population-based study. BJU Int 2009;103(12):1647–54.; Armstrong A. J., Garrett-Mayer E. S., Yang Y. C. et al. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res 2007;13:6396–403.; Fizazi K. Does Gleason score (GS) predict efficacy of abiraterone acetate (AA) therapy in patients (pts) with metastatic castrationresistant prostate cancer (mCRPC)? An analysis of AA phase 3 trials. J Clin Oncol 2014;32(suppl 4), abstr 20.; Ponda Gr. R., Sonpavdeb G., de Witc R. et al. The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer. Eur Urol 2014;65:3–6.; Xie W., Nakabayashi M., Regan M. M., Oh W. K. Higher prostate-specific antigen levels predict improved survival in patients with hormone-refractory prostate cancer who have skeletal metastases and normal serum alkaline phosphatase. Cancer 2007;110(12):2709–15.; https://oncourology.abvpress.ru/oncur/article/view/457

الاتاحة: https://oncourology.abvpress.ru/oncur/article/view/457
https://doi.org/10.17650/1726-9776-2015-11-2-77-84

المؤلفون: V. Matveev B., A. Karseladze I., A. Kazaryan P., A. Khachaturyan V., B. Kamolov Sh., O. Gigiadze V., S. Kalinin A., В. Матвеев Б., А. Карселадзе И., А. Казарян П., А. Хачатурян В., Б. Камолов Ш., О. Гигиадзе В., С. Калинин А.

المصدر: Cancer Urology; Том 7, № 4 (2011); 90-95 ; Онкоурология; Том 7, № 4 (2011); 90-95 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2011-7-4

مصطلحات موضوعية: bladder cancer, recurrent bladder cancer, fluorescence in situ hybridization, genetic disorders, рак мочевого пузыря, рецидив рака мочевого пузыря, флуоресцентная in situ гибридизация, генетические нарушения

وصف الملف: application/pdf

Relation: https://oncourology.abvpress.ru/oncur/article/view/228/245; Halling K.C., Kipp B.R. Fluorescence in situ hybridization in diagnostic cytology. Hum Pathol 2007;38:1137–44.; Halling K.C., Kipp B.R. Adv Bladder Cancer Detection Using FISH (UroVysion Assay). Anat Pathol 2008;15:279−86.; Kipp B.R., Tanasescu M., Else T.A. et al. Quantitative fluorescence in situ hybridization and its ability to predict bladder cancer recurrence and progression to muscle-invasive bladder cancer. J Mol Diagn 2009;11(2):148−54.; Richter J., Jiang F., Gorog J.P. et al. Marked genetic differences between stage pTa and stage pT1 papillary bladder cancer detected by comparative genomic hybridization. Cancer Res 1997;57: 2860–4.; Fadl-Elmula I., Gorunova L., Mandahl N. et al. Karyotypic characterization of urinary bladder transitional cell carcinomas. Genes Chromosomes Cancer 2000;29:256–65.; Sarosdy M.F., Schellhammer P., Bokinsky G. et al. Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. J Urol 2002;168:1950–4.; Клиническая онкоурология. Под ред. Б.П. Матвеева. М.: Вердана, 2003. 717 с.; Wang M.R., Perissel B., Taillandier J. et al. Nonrandom changes of chromosome 10 in bladder cancer. Detection by FISH to interphase nuclei. Cancer Genet Cytogenet 1994;73(1):8−10.; Cajulis R.S., Haines G.K . 3rd, Frias-Hidvegi D. et al. Cytology, flow cytometry, image analysis, and interphase cytogenetics by fluorescence in situ hybridization in the diagnosis of transitional cell carcinoma in bladder washes: a comparative study. Diagn Cytopathol 1995;13(3):214−24.; Pycha A., Mian C., Haitel A. et al. Fluorescence in situ hybridization identifies more aggressive types of primarily noninvasive (stage pTa) bladder cancer. J Urol 1997;157:2116–9.; Zhang F.F., Arber D.A., Wilson T.G. et al. Toward the validation of aneusomy detection by fluorescence in situ hybridization in bladder cancer: comparative analysis with cytology, cytogenetics, and clinical features predicts recurrence and defines clinical testing limitations. Clin Cancer Res 1997;3:2317–28.; Reeder J.E., O'Connell M.J., Yang Z. et al. DNA cytometry and chromosome 9 aberrations by fluorescence in situ hybridization of irrigation specimens from bladder cancer patients. Urology 1998;51(5A Suppl):58−61.; Marano A., Pan Y., Li C. et al. Chromosomal numerical aberrations detected by fluorescence in situ hybridization on bladder washings from patients with bladder cancer. Eur Urol 2000;37(3):358−65.; Stamouli M.I., Panani A.D., Ferti A.D. et al. Detection of genetic alterations in primary bladder carcinoma with dual-color and multiplex fluorescence in situ hybridization. Cancer Genet Cytogenet 2004;149(2):107−13.; Kiemeney L.A., Schoenberg M. Familial transitional cell carcinoma. J Urol 1996;156(3):867−72.; Sandberg A.A., Berger C.S. Review of chromosome studies in urological tumors. II. Cytogenetics and molecular genetics of bladder cancer. J Urol 199;151(3):545−60.; Pycha A., Mian C., Posch B. et al. Numerical chromosomal aberrations in muscle invasive squamous cell and transitional cell cancer of the urinary bladder: an alternative to classic prognostic indicators? Urology 1999;53(5):1005−10.; Sokolova I.A., Halling K.C., Jenkins R.B. et al. The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine. J Mol Diagn 2000; 2:116–23.; Cajulis R.S., Haines G.K. III, Frias-Hidvegi D. et al. Interphase cytogenetics as an adjunct in the cytodiagnosis of urinary bladder carcinoma. A comparative study of cytology, flow cytometry and interphase cytogenetics in bladder washes. Anal Quant Cytol Histol 1994;16:1–10.; Bubendorf L., Grilli B. UroVysion multiprobe FISH in urinary cytology. Methods Mol Med 2004;97:117–31.; http://www.nikon-microscope.ru/fish_dna.htm; Halling K.C. Vysis UroVysion for the detection of urothelial carcinoma. Expert Rev Mol Diagn 2003;3:507–19.; Bubendorf L., Grilli B., Sauter G. et al. Multiprobe FISH for enhanced detection of bladder cancer in voided urine specimens and bladder washings. Am J Clin Pathol 2001;116:79–86.; Halling K.C., King W., Sokolova I.A. et al. A comparison of BTA stat, hemoglobin dipstick, telomerase and Vysis UroVysion assays for the detection of urothelial carcinoma in urine. J Urol 2002;167:2001–6.; Halling K.C., King W., Sokolova I.A. et al. A comparison of cytology and fluorescence in situ hybridization for the detection of urothelial carcinoma. J Urol 2000;164(5):1768−75.; Halling K.C., Kipp B.R. Fluorescence in situ hybridisation for the detection of bladder cancer. Eur Ren Genitourinary Dis 2006; 2:51–4.; Laudadio J., Keane T.E., Reeves H.M. et al. Fluorescence in situ hybridization for detecting transitional cell carcinoma: Implications for clinical practice. Urologic Oncology: Seminars and Original Investigations 2006;24(3):270−1.; Gudjуnsson S., Isfoss B.L., Hansson K. et al. The value of the UroVysion assay for surveillance of non-muscle-invasive bladder cancer. Eur Urol 2008;54(2):402−8.; Башкатов С.В. Прогностическое значение молекулярно-цитогенетических и молекулярно-биологических нарушений в клетках поверхностной уротелиальной карциномы. Автореф. дис. … канд. мед. наук, 2008, 20 с.; Van Rhijn B.W., van der Poel H.G., van der Kwast T.H. Urine markers for bladder cancer surveillance: a systematic review. Eur Urol 2005;47(6):736−48.; May M., Hakenberg O.W., Gunia S. et al. Comparative diagnostic value of urine cytology, UBC-ELISA, and fluorescence in situ hybridization for detection of transitional cell carcinoma of urinary bladder in routine clinical practice. Urology 2007; 70(3) 449−53.; Skacel M., Fahmy M., Brainard J.A. et al. Multitarget fluorescence in situ hybridization assay detects transitional cell carcinoma in the majority of patients with bladder cancer and atypical or negative urine cytology. J Urol 2003; 169:2101–5.; Yoder B.J., Skacel M., Hedgepeth R. et al. Reflex UroVysion testing of bladder cancer surveillance patients with equivocal or negative urine cytology: a prospective study with focus on the natural history of anticipatory positive findings. Am J Clin Pathol 2007;127:295–301.; Kipp B.R., Karnes R.J., Brankley S.M. et al. Monitoring intravesical therapy for superficial bladder cancer using fluorescence in situ hybridization. J Urol 2005;173:401–4.; Mengual L., Marin-Aguilera M., Ribal M.J. et al. Clinical utility of fluorescent in situ hybridization for the surveillance of bladder cancer patients treated with bacillus Calmette-Guerin therapy. Eur Urol 2007; 52:752–9.; Pycha A., Mian C., Hofbauer J. et al. Does topical instillation therapy influence chromosomal aberrations in superficial bladder cancer? J Urol 1998; 159(1):265−9.; https://oncourology.abvpress.ru/oncur/article/view/228

الاتاحة: https://oncourology.abvpress.ru/oncur/article/view/228
https://doi.org/10.17650/1726-9776-2011-7-4-90-95

المؤلفون: I. Skvortsov Ya., B. Kamolov Sh., K. Khafizov O., A. Pavlovskaya I., Ya. Vishnevskaya V., S. Gutorov L., K. Figurin M., V. Matveev B., И. Скворцов Я., Б. Камолов Ш., К. Хафизов О., А. Павловская И., Я. Вишневская В., С. Гуторов Л., К. Фигурин М., В. Матвеев Б.

المصدر: Cancer Urology; Том 7, № 2 (2011); 92-95 ; Онкоурология; Том 7, № 2 (2011); 92-95 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2011-7-2

مصطلحات موضوعية: prostate cancer, neuroendocrine cells, differentiation, biological markers, рак предстательной железы, нейроэндокринные клетки, дифференцировка, биологические маркеры

وصف الملف: application/pdf

Relation: https://oncourology.abvpress.ru/oncur/article/view/168/183; Abrahamsson P.A. Neuroendocrine differentiation and hormone-refractory prostate cancer. Prostate 1996;(Suppl 6):3–8.; Aprikian A.G., Cordon-Cardo C., Fair W.R. and Reuter V.E. Characterization of neuroendocrine differentiation in human benign prostate and prostatic adenocarcinomas. Cancer 1993;71:3952–65.; VACURG. Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet 1967;124:1011–7 .; Pretl K. Zur frage der endokrinie der menschlichen vorsteherdruse. Virch Arch Path Anat 1944;312:392–9.; Pearse A.G.E. The cytochemistry and ultrastructure of polypeptide hormoneproducing cells APUD series and the embryologic, physiologic and pathologic implications of the concept. J Histochem Citochem 1969;17:303–13.; Helpap B. Morphology and therapeutic strategies for neuroendocrine tumors of the genitourinary tract. Cancer 2002;95:1415–20.; Duran I., Berthold D.R., Pond G.R. et al. Meeting: 2007 Prostate Cancer Symposium. Abstract No:253 Neuroendocrine carcinoma of the prostate: Review of 14 cases at a single institution from 1988–2004.; di Sant’Agnese P.A., Davis N., Chen M. et al. Age-related changes in the neuroendocrine (endocrine-paracrine) cell population and the serotonin content of the guinea pig prostate. Laboratory Invest 1987;57:729–34.; Battaglia S., Casali A.M., Botticelli A.R. Agerelated distribution of endocrine cells in the humane prostate: a quantitative study. Virchows Arch 1994;424:165–8.; di Sant’Agnese, P. A. Neuroendocrine differentiation in prostatic carcinoma. Cancer 1995;(Suppl 75):1850–9.; Abrahamsson P.A., Waldstrom L.B., Almmets J. Peptide-hormone and serotoninimmunoreactive cells in normal and hyperplastic glands. Pathol Res Prat 1986;181:675–83.; Huttner W.B., Gerdes H.H., Rosa P. The granin (chromogranin/ secretogranin) family. TIBS 1991;16:27–30.; Wu J.T., Wu T.L., Chang C.P. et al. Different patterns of serum chromogranin A in patients with prostate cancer with and without undergoing hormonal therapy. J Clin Lab Anal 1999;13:308–11.; Zifa E., Fillion G. 5-hydroxytriptamine receptors. Pharmacol Rev 1992;44:401–58.; Iwamura M., di Sant’Agnese P., Wu G. et al. Immunohistochemical localization or parathyroid hormone-related protein in human prostate cancer. Cancer Res 1993;53:1724–6.; Bonkhoff H., Stein U., Remberger K. Endocrine-paracrine cell types in the prostate and prostatic adenocarcinoma are postmitotic cells. Hum Pathol 1995;26:167–70.; Nakada S.Y., di Sant’Agnese P.A., Moynes R.A. et al. The androgen receptor status of neuroendocrine cells in human benign and malignant prostatic tissue. Cancer Res 1993;53:1967–70.; More L.B., Buettner R., Ahmad N. et al. Prostate adenocarcinoma: cellular and molecular abnormalities. Cancer Control 2001;8(6):551–61.; Sciarra A., Mariotti G., Gentile V. et al. Neuroendocrine differentiation in human prostate tissue: is it detectable and treatable? BJU International 2003;91:438–45.; Berruti A., Dogliotti L., Mosca A., Bellina M. Circulating neuroendocrine markers in patients with prostate carcinoma. Cancer 2000;88:2590–6.; Krijnen J.L., Bongdanowicz J., Seldenrijk C.A. et al. The prognostic value of neuroendocrine differentiation in adenocarcinoma of the prostate in relation to progression of disease after endocrine therapy. J Urol 1997;158:171–4.; Stein M., Bernstein Z., Abacioglu U. et al. Small cell (neuroendocrine) carcinomas of the prostate: etiology, diagnosis, prognosis and therapeutic implications – a retrospective study of 30 patients from rare cancer network. Am J Med Scienc 2008;336(6):478–88.; Eble J.N. , Sauter G., Epstein J.I. et. al. Pathology and genetics of tumours of the urinary system and male genital organs. Lyon, 2004; p. 207–9.; https://oncourology.abvpress.ru/oncur/article/view/168

الاتاحة: https://oncourology.abvpress.ru/oncur/article/view/168
https://doi.org/10.17650/1726-9776-2011-7-2-92-95

المؤلفون: G. Akhverdieva I., E. Sanai B., V. Panov O., I. Tyurin E., I. Gubsky L., B. Kamolov Sh., A. Khachaturyan V., Г. Ахвердиева И., Э. Санай Б., В. Панов О., И. Тюрин Е., И. Губский Л., Б. Камолов Ш., А. Хачатурян В.

المصدر: Cancer Urology; Том 9, № 4 (2013); 25-36 ; Онкоурология; Том 9, № 4 (2013); 25-36 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2013-9-4

مصطلحات موضوعية: prostate cancer, recurrence, multiparametric magnetic resonance imaging, diffusion-weighted image, dynamic contrast ratio, binary logistic repression, рак предстательной железы, рецидив, мультипараметрическая магнитно-резонансная томография, диффузионно взвешенное изображение, динамическое контрастирование, бинарная логистическая регрессия

وصف الملف: application/pdf

Relation: https://oncourology.abvpress.ru/oncur/article/view/140/156; American Cancer Society. Cancer Facts and Figures 2008. Atlanta, GA: American Cancer Society; 2008.; Статистика злокачественных новообразований в России и странах СНГ в 2004 году. Под ред. М. И. Давыдова и Е. М. Аксель. Вестн РОНЦ им. Н. Н. Блохина РАМН. 2006;17 (3): 1–132.; Hricak H., White S., Vigneron D. et al. Cancer of the prostate gland: MR imaging with pelvic-phased-array coils versus integrated endorectal-pelvic phased – array coils. Radiology 1994;193:703–9.; Dono van J., Hamdy F., Neal D. et al. ProtecT Study Group. Prostate Testing for Cancer and Treatment (ProtecT) feasibility study. Health Technol Assess 2003:7 (14):1–88.; Eichler K., Hempel S., Wilby J. et al. Diagnostic value of systematic biopsy methods in the investigation of prostate cancer: a systematic review. J Urol 2006;175 (5):1605–12.; Lee F., Torp-Pedersen S. T., Siders D. B. et al. Transrectal ultrasound in the diagnosis and staging of prostate cancer. Radiology 1989;170 (3 Pt 1):609–15.; Lee N., Newhouse J. H., Olsson C. A. et al. Which patients with newly diagnosed prostate cancer need a computed tomography scan of the abdomen and pelvis? An analysis based on 588 patients. Urology 1999;54 (3):490–4.; Smith J.A. Jr, Scardino P.T., Resnick M.I., et al. Transrectal ultrasound versus digital rectal examination for the staging of carcinoma of the prostate: results of a prospective multi-institutional trial. J Urol 1997;157 (3):902–6.; Sauvain J.L., Palascak P., Bourscheid D., et al. Value of power Doppler and 3D vascular sonography as a method for diagnosis and staging of prostate cancer. Eur Urol 2003;44 (1):21–30.; Smeenge M., Mischi M., Laguna Pes M.P., et al. Novel contrast-enhanced ultrasound imaging in prostate cancer. World J Urol 2011;29 (5):581–7.; Zalesky M., Urban M., Smerhovský Z., et al. Value of power Doppler sonography with 3D reconstruction in preoperative diagnostics of extraprostatic tumor extension in clinically localized prostate cancer. Int J Urol 2008;15 (1):68–75.; Hricak H., Dooms G. C., McNeal J. E. MR imaging of thr prostate gland. Normal anatomy. Am J Roenthenol 1987;148:51–64.; Schnall M. D., Pollack H. M. Magnetic resonance imaging of the prostate. Urol Radiol 1990;12:109–15.; Yu K. K., Hricak H. Imaging prostate cancer. Radiol Clin North Am 2000;38 (1):59–85.; Jager G. J., Ruijet E. T., van de Kaa C. A. et al. Local staging of prostate cancer with endorectal MR imaging: correlation with histopathology. Am J Roentgenol 1996;166:845–52.; Lemaitre L., Puech P., Poncelet E. et al. Dynamic contrast-enhanced MRI of anterior prostate cancer: morphometric assessment and correlation with radical prostatectomy findings. Eur Radiol 2009;19 (2):470–80.; Kirkham A. P., Emberton M., Allen C. How good is MRI detecting and characterizing cancer within the prostate? Eur Urol 2006;50:1163–74.; Biondetti P. R., Lee J. K., Ling D. et al. Clinical stage B prostate carcinoma: staging with MR imaging. Radiolgy1987;162:325–9.; Presti J. C. Jr, Hricak H., Narayan P. A. et al. Local staging of prostatic carcinoma: comparison of transrectal sonography and endorectal MR imaging. AJR Am J Roentgenol 1996;166:103–8.; Tempany C. M., Zhou X., Zerhouni E. A. et al. Staging of prostate cancer: results of Radiology Diagnostic Oncology Group project comparison of three MR imaging techniques. Radiology 1994;192:47–54.; Jager G. J., Ruijet E. T., van de Kaa C. A. et al. Local staging of prostate cancer with endorectal MR imaging: correlation with histopathology. Am J Roentgenol1996;166:845–52.; Gossmann A., Okuhata Y., Shames D. M. et al. Prostate cancer tumor grade differentiation with dynamic contrast-enhanced MR imaging in the rat: comparison of macromolecular and small-molecular contrast media – preliminary experience. Radiology 1999;213 (1): 265–72.; Kuhn M., Huttmann P., Spielhaupter E. et al. Clinical value of native and contrast enhanced MRI in staging prostatic carcinoma before planned radical prostatectomy. ROFO Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 2001;173 (7):595–600.; Bree R. L. The role of color Doppler and staging biopsies in prostate cancer detection. Urology 1997;49 (3):31–5.; Padhani A. R., Gapinski C. J., Macvicar D. A. et al. Dynamic contrast enhanced MRI of prostate cancer correlation with morphology and tumour stage, histological grade and PSA. Clin Radiol 2000;55 (2):99–109.; Ogura K., Maekawa S., Okubo K. et al. Dynamic endorectal magnetic resonance imaging for local staging and detection of neurovascular bundle involvement of prostate cancer: correlation with histopathologic results. Urology 2001; 57 (4):721–36.; Hricak H., White S., Vigneron D. et al. Carcinoma of the prostate gland: MR imaging with pelvic phased-array coils versus integrated endorectal-pelvic phased-array coils. Radiology 1994; 193:703–10.; Borchers H., Tache J., Biesterfeld S.et al. Improved diagnosis of pT2 prostate cancer by gadolinium enhanced magnetic resonance imaging. Eur Urol 2001; 39 (5):211–6.; Perroti M., Kaufman R. P., Jennings T. A. et al. Endorectal coil magnetic resonance imaging in clinically localized prostate cancer: is it accurate? Urology 1996;156:106–9.; Poularis V., Witzsch U., de Vries R. Magnetic resonance imaging (MRI) with dynamic contrast enhancement in local staging of prostate cancer. Eur Urol 2001;39 (5):1–216.; Tanaka N., Samma S., Jokko M. Diagnostic usefulness of endorectal magnetic resonance imaging with dynamic contrastenhancement in patients with localized prostate cancer: mapping studies with biopsy specimens. Int J Urol 1999;6(12):593–9.; Field Andy. Discovering Statistics using IBM SPSS Statistics. SAGE Publications Ltd, London EC1Y 1SP, 2005.; Бююль А., Цёфель П. SPSS: искусство обработки информации. М.: DiaSoft, 2005.; Vilanova J. C., Barcelo-Vidal C., Comet J. et al. Usefulness of prebiopsy multifunctional and morphologic MRI combined with free-tototal prostate-specific antigen ratio in the detection of prostate cancer. AJR Am J Roentgenol 2011;196:715–22.; Walz J., Graefen M., Chun F. K. et al. High incidence of prostate cancer detected by saturation biopsy after previous negative biopsy series. Eur Urol 2006;50 (3):498–505.; https://oncourology.abvpress.ru/oncur/article/view/140

الاتاحة: https://oncourology.abvpress.ru/oncur/article/view/140
https://doi.org/10.17650/1726-9776-2013-9-4-25-36

المؤلفون: V. Matveev B., A. Karseladze I., B. Kamolov Sh., A. Khachaturyan V., N. Cheban L., В. Матвеев Б., А. Карселадзе И., Б. Камолов Ш., А. Хачатурян В., Н. Чебан Л.

المصدر: Cancer Urology; Том 9, № 1 (2013); 74-76 ; Онкоурология; Том 9, № 1 (2013); 74-76 ; 1996-1812 ; 1726-9776 ; 10.17650/1726-9776-2013-9-1

مصطلحات موضوعية: Prostate, stromal tumor, prostatic tumor in young patients, предстательная железа, стромальная опухоль, опухоль предстательной железы у молодых пациентов

وصف الملف: application/pdf

Relation: https://oncourology.abvpress.ru/oncur/article/view/198/213; Kakuta Y., Kobayashi Y., Tanaka M. et al. A case of prostatic stromal tumor of uncertain malignant potential. Hinyokika Kiyo 2005;51(12):843–6; discussion 846–7.; Herawi M., Epstein J.I. Specialized stromal tumors of the prostate: a clinicopathologic study of 50 cases. Am J Surg Pathol 2006;30(6):694–704.; Laturnus J.M., Gebhard M., Sommerauer M. et al. Stromal tumour of uncertain malignant potential of the prostate (STUMP) – a case report. 2010;41(3):197–9.; https://oncourology.abvpress.ru/oncur/article/view/198

الاتاحة: https://oncourology.abvpress.ru/oncur/article/view/198
https://doi.org/10.17650/1726-9776-2013-9-1-74-76